Parallel

Parallel is the first tech-forward provider of learning assessments and treatment solutions for students with learning differences. The company specializes in virtual neurodevelopmental assessments and support services for conditions such as dyslexia, dysgraphia, dyscalculia, and executive dysfunction.

Children Education Therapeutics Training

$61.25M

Latest Funding

Series A

Latest Funding Stage

2024-01-11

Funding Date

111

Employees

United States

Location

New York, New York

City & State

Sales-Ready Summary

Parallel Learning recently raised $61.25M in Series A funding and is actively hiring Speech Language Pathologists, signaling potential expansion in their services and a need for related tools and resources.

Key Contacts
Unlock Contact Information

Upgrade to access founder details

Upgrade Now
Open Positions
View Careers Page
Hiring For
Speech Language Pathologists
Unlock Tech Stack Data

Upgrade to access technology insights

Upgrade Now

Similar Startups

Reddy
Reddy Logo

Reddy is an AI-powered platform that helps turn rookie hires into all-stars. Our talent hub allows for large enterprises to connect Recruiting, L&D and Operations in one home, with AI tools for each department that are tuned to your business' DNA. By optimizing talent pipelines, Reddy allows users to decrease turnover while increasingsales and support.

EG 427
EG 427  Logo

EG 427 develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and its ability to establish lifelong latency in peripheral neurons to ensure highly specific and durable expression of transgenes to treat patients with severe, chronic and localized diseases, enabling physicians to cure neurogenic bladder disorders post a spinal cord injury.

Reverb Therapeutics
Reverb Therapeutics Logo

Reverb Therapeutics uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokine, enabling cancer patients and the healthcare sector to redirect endogenous cytokines already in the body to cells of interest and treat cancer.

EnPlusOne Biosciences
EnPlusOne Biosciences Logo

EnPlusOne Biosciences offers enzymatic-based RNA synthesis to address systemic issues inherent to existing chemical synthesis methods and the expansion of RNA therapeutics has uncovered key issues including scaled production and access to innovative therapeutic modifications, enabling the manufacturing process to deliver therapeutic RNA at a commercial scale sustainably.